Matinas BioPharma Holdings Inc - Asset Resilience Ratio
Matinas BioPharma Holdings Inc (MTNB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Matinas BioPharma Holdings Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Matinas BioPharma Holdings Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MTNB asset base.
Liquid Assets Composition Over Time
This chart breaks down Matinas BioPharma Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore MTNB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Matinas BioPharma Holdings Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Matinas BioPharma Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Matinas BioPharma Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Matinas BioPharma Holdings Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Matinas BioPharma Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $12.64 Million | -- |
| 2023-12-31 | 35.73% | $8.97 Million | $25.10 Million | +7.92pp |
| 2022-12-31 | 27.81% | $21.93 Million | $78.87 Million | -18.81pp |
| 2021-12-31 | 46.62% | $28.59 Million | $61.33 Million | -18.54pp |
| 2020-12-31 | 65.17% | $46.25 Million | $70.97 Million | +51.24pp |
| 2019-12-31 | 13.93% | $5.61 Million | $40.24 Million | +12.85pp |
| 2017-12-31 | 1.07% | $155.00K | $14.42 Million | -0.51pp |
| 2016-12-31 | 1.59% | $156.00K | $9.82 Million | +0.40pp |
| 2015-12-31 | 1.19% | $100.00K | $8.41 Million | -1.79pp |
| 2014-12-31 | 2.97% | $100.00K | $3.36 Million | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more